Sidney Smith, MD
Psychiatry · Metairie, LANPI 1922148162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 534 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$673
- Alkermes, Inc.$599
- Teva Pharmaceuticals USA, Inc.$557
- Lundbeck LLC$542
- plus $5K from 25 others
What the payments were for
- Food & beverage$10,15099%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $2,135 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,035 |
| Johnson & Johnson | 45 | $673 |
| Alkermes, Inc. | 28 | $599 |
| Teva Pharmaceuticals USA, Inc. | 33 | $557 |
| Lundbeck LLC | 30 | $542 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $473 |
| Almatica Pharma LLC | 23 | $424 |
| Supernus Pharmaceuticals, Inc. | 14 | $420 |
| Vanda Pharmaceuticals Inc. | 20 | $385 |
| Axsome Therapeutics, Inc. | 19 | $384 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $334 |
| Jazz Pharmaceuticals Inc. | 14 | $315 |
| Tris Pharma Inc | 18 | $309 |
| Neurocrine Biosciences, Inc. | 9 | $259 |
| Noven Therapeutics, LLC | 14 | $228 |
| Eisai Inc. | 6 | $227 |
| Sunovion Pharmaceuticals Inc. | 11 | $193 |
| Bioxcel Therapeutics, Inc. | 4 | $179 |
| Corium, LLC | 10 | $150 |
| Bausch Health US, LLC | 6 | $128 |
| Acadia Pharmaceuticals Inc | 5 | $94 |
| Indivior Inc. | 4 | $54 |
| Shire North American Group Inc | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Brainsway USA Inc | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Merck | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,282 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 13 | $37,846 |
| PerserisRisperidone | 12 | $37,052 |
| Invega SustennaPaliperidone Palmitate | 11 | $22,927 |
| FanaptIloperidone | 16 | $21,908 |
| Risperdal ConstaRisperidone Microspheres | 44 | $18,649 |
| Memantine Hcl | 658 | $14,173 |
| BelsomraSuvorexant | 23 | $10,539 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $10,319 |
| ProzacFluoxetine Hcl | 12 | $9,878 |
| FetzimaLevomilnacipran Hcl | 15 | $9,782 |
| Bupropion XlBupropion Hcl | 541 | $9,595 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,557 |
| Vilazodone Hcl | 98 | $8,524 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 488 | $8,501 |
| Clozapine | 138 | $8,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $673 | $41,57655 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,035 | $37,84613 claims |
| Indivior Inc.Perseris | $54 | $37,05212 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $385 | $21,90816 claims |
| MerckBelsomra | $15 | $10,53923 claims |
| AbbVieFetzima | $2,135 | $9,78215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $334 | $8,55717 claims |
| Almatica Pharma LLCSertraline Hcl | $424 | $4,932581 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Metairie
- Charles ChesterMetairie$14K
- Teri SchwarzMetairie$13K
- Julie CeasarMetairie$12K
- Kenneth SumnerMetairie$12K
- Jonathon RynningMetairie$11K
- Jose RodriguezMetairie$9K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.